
Pro Medicus Ltd (ASX: PME) shares could be dirt cheap right now.
That’s the view of analysts at Bell Potter, who are urging investors to buy the health imaging technology company’s shares while they are down.
What is the broker saying?
Bell Potter was pleased with news that Northwestern Medicine has renewed with the ASX 200 tech stock for a further five years on improved terms. It said:
Northwestern Medicine has signed a 5 year extension with PME for the Visage Viewer at increased rates and with an increased minimum deal value. Northwestern is one of the largest healthcare providers in the state of Illinois and a leading academic medical centre and remains a highly valuable client. Contract value is upgraded from $22m to $37m over five years.
PME continues to win new business in the United States, last week announcing the signing of a five year $23m deal with University of Maryland Medical System covering Visage 7 Viewer and Visage Workflow â but again no archive (Maryland already has an off premises archive). We understand the incumbent was Carestream (a company owned by Phillips).
Outside this, Bell Potter has trimmed its revenue forecast slightly to reflect a delay in revenues from the major Trinity Health contract and a weaker US dollar. It adds:
FY26 revenue forecast is reduced by a further 3.4% to $261m owing to amendments in the commencement date for exam revenues on major new contract implementations at Trinity Health and U. Colorado. The weaker US$ is also expected to have a material impact on revenues in the current period.
Longer term, the outlook remains strong with PME FY27 exam revenues expected to benefit from full period benefit of implementations in the current half including the two largest cohorts of the Trinity Health contract plus the Big Bang implementation at U. Colorado covering radiology and cardiology.
Time to buy this ASX 200 tech stock?
According to the note, the broker has retained its buy rating on the ASX 200 tech stock with a slightly reduced price target of $226.00 (from $240.00).
Based on its current share price of $132.38, this implies potential upside of 70% for investors over the next 12 months.
Commenting on its buy recommendation, Bell Potter said:
PME continues to win new work and retains 100% of its existing client base. The stock is trading 60% below it all time high â not all attributable to the re-rating of its software revenues stream i.e. the law of large numbers is catching up, hence harder now for the company to maintain +30% EPS growth. Retain buy, PT amended to $226 following earnings amendments.
The post This dirt cheap ASX 200 tech stock could rise 70% appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Still down 40%, are Pro Medicus shares primed to break out?
- 5 things to watch on the ASX 200 on Tuesday
- Why these ASX 200 stocks could be perfect for buy and hold investors
- Why Monash IVF, Pro Medicus, Telix, and Woodside shares are storming higher today
- Why are Pro Medicus shares outperforming the market on Monday?
Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.








